Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?-Reference-Cited by-同舟云学术

Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?

Published:2007-01 Issue:1 Volume:29 Page:196-209
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Sarawate Chaitanya A.,Cziraky Mark J.,Stanek Eric J.,Willey Vincent J.,Corbelli John C.,Charland Scott L.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference52 articles.

1. Heart disease and stroke statistics2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee;Thom;Circulation,2006

2. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: Findings from the National Health and Nutrition Examination Survey, 1999 to 2000;Ford;Circulation,2003

3. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): Case-control study;Yusuf;Lancet,2004

4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S);Lancet,1994

5. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial;Lancet,2002

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes;Vascular Health and Risk Management;2013-10

2. Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial;The Pharmacogenomics Journal;2013-08-27

3. Impact of optimal lipid value achievement between 2005 and 2009 in patients with mixed dyslipidaemia on cardiovascular event rates;International Journal of Clinical Practice;2011-03-15

4. The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome;Endocrinología y Nutrición (English Edition);2011-01

5. Estudio REALIST (REsiduAl risk, LIpids and Standard Therapies): Un análisis del Riesgo Residual dependiente del perfil lipídico en el síndrome coronario agudo;Endocrinología y Nutrición;2011-01